For decades, the hunt for a single molecular target that bridges multiple forms of neurodegeneration has remained elusive. A new mechanistic discovery repositions a well-known axon-destruction enzyme as a central executioner in a far wider range of neuronal death processes — with immediate implications for Parkinson's disease, stroke, and traumatic brain injury research.
SARM1, an NAD+-consuming enzyme previously understood primarily as the key driver of pathological axon degeneration, has now been identified as an essential component of parthanatos — a distinct programmed cell death pathway triggered by DNA damage. The mechanism hinges on NAD+ metabolism: when DNA damage hyperactivates the repair enzyme PARP1, cellular NAD+ is catastrophically depleted and the NMN-to-NAD+ ratio spikes, which allosterically activates SARM1. Critically, SARM1 proved necessary for downstream parthanatos hallmarks including mitochondrial membrane depolarization and nuclear translocation of apoptosis-inducing factor (AIF). Furthermore, SARM1 inhibition provided potent protection against dopaminergic neuron toxicity induced by MPP+ (the active Parkinson's-linked neurotoxin) and against NMDA receptor-mediated excitotoxicity — two mechanistically distinct but clinically urgent threats.
This finding substantially widens the therapeutic aperture for SARM1 inhibitors, several of which are already in early clinical development for peripheral neuropathies and axonopathies. Until now, these compounds were considered relevant only to diseases defined by axon loss, such as Charcot-Marie-Tooth disease or chemotherapy-induced neuropathy. Placing SARM1 at the intersection of parthanatos and excitotoxicity makes it a candidate target for acute neurological injuries — ischemic stroke and traumatic brain injury — where NMDA excitotoxicity is a primary driver of neuronal loss. The study's mechanistic precision is a genuine strength, though translation from cellular models to in vivo mammalian disease remains a critical next step. If replicated in animal models, this could represent a paradigm-shifting expansion of SARM1 inhibitor utility across the neurodegenerative disease spectrum.